Michael Kaufman
2020
In 2020, Michael Kaufman earned a total compensation of $1.2M as Chief Manufacturing Officer at Mersana Therapeutics, a 41% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $184,848 |
|---|---|
| Option Awards | $459,324 |
| Salary | $398,380 |
| Stock Awards | $164,269 |
| Other | $7,000 |
| Total | $1,213,821 |
Kaufman received $459.3K in option awards, accounting for 38% of the total pay in 2020.
Kaufman also received $184.8K in non-equity incentive plan, $398.4K in salary, $164.3K in stock awards and $7K in other compensation.
Rankings
In 2020, Michael Kaufman's compensation ranked 7,790th out of 13,090 executives tracked by ExecPay. In other words, Kaufman earned more than 40.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,790 out of 13,090 | 41st |
Division Manufacturing | 3,288 out of 5,621 | 42nd |
Major group Chemicals And Allied Products | 1,333 out of 2,254 | 41st |
Industry group Drugs | 1,156 out of 1,954 | 41st |
Industry Pharmaceutical Preparations | 860 out of 1,459 | 41st |
Source: SEC filing on April 27, 2021.
Kaufman's colleagues
We found four more compensation records of executives who worked with Michael Kaufman at Mersana Therapeutics in 2020.
2020
Arvin Yang
Mersana Therapeutics
Chief Medical Officer
2020
Anna Protopapas
Mersana Therapeutics
Chief Executive Officer
2020
Timothy Lowinger
Mersana Therapeutics
Chief Science and Technology Officer
2020
Brian DeSchuytner
Mersana Therapeutics
Senior Vice President, Finance & Product Strategy
News
Mersana Therapeutics CEO Anna Protopapas' 2021 pay jumps 226% to $8.3M
April 29, 2022
Mersana Therapeutics Chief Medical Officer Arvin Yang receives $4.5M in 2020
April 27, 2021
Mersana Therapeutics CEO Anna Protopapas' 2019 pay falls 33% to $1.7M
April 20, 2020
Mersana Therapeutics CEO Anna Protopapas' 2018 pay jumps 184% to $2.6M
April 23, 2019